Ptc Therapeutics Inc Revenue Growth Rates (PTCT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ptc Therapeutics inc   (NASDAQ: PTCT)
 

PTCT's Revenue Growth by Quarter and Year

Ptc Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PTCT/growth
https://api.csimarket.com/api/v1/companies/PTCT/fundamentals
https://api.csimarket.com/api/v1/companies/PTCT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PTCT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 357.81
2nd Quarter June 360.52
1st Quarter March 272.55
FY 990.88

PTCTs Annual Revenue
Ptc Therapeutics Inc 's Revenue in the fiscal year 2025 $ 1,730.66 millions
Ptc Therapeutics Inc 's Revenue in the fiscal year 2024 $ 806.78 millions
Ptc Therapeutics Inc 's Revenue in the fiscal year 2023 $ 937.82 millions
Ptc Therapeutics Inc 's Revenue in the fiscal year 2022 $ 698.80 millions
Ptc Therapeutics Inc 's Revenue in the fiscal year 2021 $ 538.59 millions




PTCT Revenue third quarter 2026 Y/Y Growth Comment
Ptc Therapeutics inc reported Revenue surge of 69.57% year on year in the third quarter 2026, to $ 357.81 millions, this is lower than Ptc Therapeutics Inc 's recent average Revenue surge of 279.59%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 37 other companies have achieved higher Revenue growth. While Ptc Therapeutics Inc ' s Revenue jump of 69.57% ranks overall at the positon no. 264 in the third quarter 2026.


PTCT Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 69.57 %
2nd Quarter June 101.54 %
1st Quarter March -76.83 %
FY   -

Financial Statements
Ptc Therapeutics Inc 's third quarter 2026 Revenue $ 357.81 millions PTCT's Income Statement
Ptc Therapeutics Inc 's third quarter 2025 Revenue $ 211.01 millions Quarterly PTCT's Income Statement


PTCT Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -0.75 %
2nd Quarter June 32.28 %
1st Quarter March 65.5 %
FY (Year on Year)   -


Back to PTCT Growth rate Comparisons >> Back to PTCT Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #38
Healthcare Sector #72
Overall #264

Revenue Y/Y Growth Statistics
High Average Low
12059.66 % 279.59 % -99.1 %
(Jun 30 2019)   (Sep 30 2014)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #38
Healthcare Sector #72
Overall #264
Revenue Y/Y Growth Statistics
High Average Low
12059.66 % 279.59 % -99.1 %
(Jun 30 2019)   (Sep 30 2014)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Ptc Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
15499.94 % 298.02 % -99.15 %
(Jun 30 2019)  


PTCT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Ptc Therapeutics Inc disclosed decrease in Revenue from the second quarter by -0.75% to $ 357.81 millions, from $ 360.52 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Ptc Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 348.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #79
Overall #348
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #79
Overall #348
Revenue Q/Q Growth Statistics
High Average Low
15499.94 % 298.02 % -99.15 %
(Jun 30 2019)  


PTCT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Ptc Therapeutics Inc disclosed decrease in Revenue from the second quarter by -0.75% to $ 357.81 millions, from $ 360.52 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Ptc Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 348.


Ptc Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 1,155.55
Y / Y Revenue Growth (TTM) -35.05 %
Year on Year Revenue Growth Overall Ranking # 168
Seqeuential Revenue Change (TTM) 14.55 %
Seq. Revenue Growth (TTM) Overall Ranking # 2660


Cumulative Revenue growth Comment
Ptc Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Ptc Therapeutics Inc 's annual Revenue growth would be -35.05% year on year to $1,156 millions.

In the Healthcare sector 48 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 168, from total ranking in previous quarter at 2707.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 49
Overall # 168

Revenue TTM Y/Y Growth Statistics
High Average Low
3395.24 %
 109.68 %
-53.96 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 381
S&P 500 # 2660
Cumulative Revenue growth Comment
Ptc Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Ptc Therapeutics Inc 's annual Revenue drop would be -35.05% year on year to $1,156 millions.

In the Healthcare sector 48 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 168, from total ranking in previous quarter at 2707.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 49
Overall # 168

Revenue TTM Y/Y Growth Statistics
High Average Low
3395.24 %
109.68 %
-53.96 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 381
S&P 500 # 2660




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PTCT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions


About Ptc Therapeutics Inc Revenue Growth Rates (PTCT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ptc Therapeutics Inc (CIK 1070081).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-120223
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ptc Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.